Clinical Trial Search

Primary: The Number of Participants With Both Clinical and Histological Evidence of Malignant Transformation of Oral Epithelial Dysplasia — 32; 46 participants

Primary: Maximum Tolerated Dose — 8 J/cm2

Primary: Light Microscopic Histologically Scored Diagnoses Pretreatment to Post Treatment — 2.36; 2.83; 1.9; 2.58 unit on histologic grade scale — p=0.048

Primary: - To Evaluate the Efficacy of Sulindac in Subjects With Early or Advanced Oral Premalignant Lesion (OPL) by Both Clinical Response (Reduction in Size of All Lesions) and…

Primary: Oral Cancer-free Survival — NA; 6.7 Months

Primary: The Primary Efficacy Variable Was the Change in the Investigator's Global Assessment of the Overall Severity of Disease From Baseline to Week 6. — 2.4; 2.45; 1.6; 2.27…

Primary: Rate of Recurrence — 8 Participants

Primary: Number and Percentage of Lesions That Were Stained Positive — 29; 28 lesions — p=0.005

Primary: Pre-treatment OSCC Morphology and PDPN Expression — 2.8; 3.4; 2.5 score on a scale from 1 to 5 — p=<0.05

Primary: OMI-20 Total Score Change From Baseline to Day 3 — 0.0; 0.0 score on a scale

Primary: Determine an Efficacious Dose (mg/cm2) of PRV111 (Cisplatin Transmucosal System) Via Number of Tumor Responses — 7 Participants

Primary: Number of Participants With no Residual Tumor Following Photodynamic Therapy (PDT) — 22 Participants

Primary: Best Overall Response Rate (BORR) — 36.4 percentage of participants

Primary: Grade 3+ Adverse Events Rate — .032; .115 events per participant

Primary: Progression Free Survival (PFS) — 3; 6; 0; 8 Participants

Primary: Change in Oral Sensitivity — -4.5; -6.0 score on a scale

Primary: Incidence of Objective Response — 32; 36; 30; 0 Participants — p=0.043

Primary: Abrasion Assessment (Number) — 3.65; 4.11 number of abrasions

Primary: WHO (World Health Organisation) Oral Mucositis Severity Score During 28 Days of Treatment, Intention to Treat Population — 0.63; 0.56 score

Primary: Median Change in Quality of Life (QOL) From Baseline to 12 Months Post Treatment — -4.2; 0; 6.3; 10.7 score on a scale

Primary: Pathologic Response. — 25; 2; 4; 4 Participants

Primary: Pink Esthetic Score (PES) at Temporary Crown Delivery. — 1; 1; 1; 1 score on a scale — p=0.0007

Primary: 2 Year Progression Free Survival After De-intensified Chemoradiotherapy (CRT) in Human Papilloma Virus (HPV)-Positive and/or p16 Positive Low-risk Oropharyngeal Squamous…

Primary: Procedure Preference and Acceptability Questionnaire and Visual Analog Scale — 7.2; 8.5; -1.3; 16.2 Units on a scale

Primary: Percent Change From Baseline to Two Weeks in Symptoms and Signs of Oral Lichen Planus (OLP) — -22; 0; -17; 0 percent change

Primary: Pathological Response — 20; 24 participants

Primary: Peri-operative Mortality at 30 Days — 0.029 proportion of participants

Primary: Change From Baseline Gingivitis at Day 14 as Measured by Non-invasive Microimaging and Gingival Index. — 0.6; 0.15 units on a scale

Primary: Percentage of Patients Free of Grade 3+ Late Toxicity — 86 percentage of participants

Primary: Reversal of Oxidative DNA Damage as Assessed by Changes in 8-hydroxy-2' -Deoxyguanosine (8OHdG) Immunostaining — 1.62 % of strongly/moderately stained nuclei — p=0.54